Tests baricitinib for long-term safety in children with juvenile arthritis
Tests the drug baricitinib in children with juvenile idiopathic arthritis, aged 1 to 17.
Plain-language title generated from the registry record
Registry title: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Key facts
- Where
- Chihuahua City, Durango, Guadalajara, México, and Monterrey, MexicoSee the 5 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teens with juvenile idiopathic arthritis who finished an earlier baricitinib study. It checks long-term safety and how well baricitinib works.
- Age
- From 1 year to under 18 years.
- Sex
- All sexes can join.
- Disease stage
- Juvenile idiopathic arthritis (JIA).
- Earlier treatment
- Must have completed a previous study of baricitinib for JIA.
Main reasons for not taking part
- Baricitinib was permanently stopped in the earlier study.
- Developed an allergy to baricitinib.
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 18 years old?
Source: NCT03773965, who can take part
Where in Mexico
- Investigacion y Biomedicina de ChihuahuaChihuahua City, MexicoTaking people
- Instituto de Investigaciones Clínicas para la SaludDurango, MexicoTaking people
- Crea de GuadalajaraGuadalajara, MexicoTaking people
- Clinstile, S.A. de C.V.México, MexicoTaking people
- Hospital Universitario Dr. Jose Eleuterio GonzálezMonterrey, MexicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT03773965
- Record updated
- 4 November 2026
- Original description
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.Read full original descriptionShow less
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
Inclusion: Participants must have completed a previous study of baricitinib for the treatment of JIA.
Exclusion: Participants must not have had a permanent discontinuation of baricitinib in the prior study; Participants must have not developed an allergy to baricitinib.